SCHEMBL22639003

SCHEMBL22639003

CN(C(=O)C(F)(F)F)c1c(C(=O)O)sc2ncccc12

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 1/20 0.46
IKBKB O14920 1/20 0.44
CHUK O15111 1/20 0.44
LIMK1 P53667 1/20 0.44
TP53 P04637 2/20 0.39
THRB P10828 1/20 0.37
ADORA2A P29274 1/20 0.36
KMT2A Q03164 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22639025 0.84 TP53 (0.41) KDM4EALDH1A1IKBKBCHUKLIMK1
SCHEMBL1697886 0.80 HDAC3 (0.32) KDM4EALDH1A1KMT2APOLBHPGD
SCHEMBL29199696 0.80 IKBKB (0.46) KDM4EALDH1A1IKBKBLIMK1KMT2A
SCHEMBL843920 0.73 KDM4E (0.56) KDM4EALDH1A1IKBKBCHUKLIMK1
SCHEMBL9539962 0.71 KDM4E (0.57) KDM4EALDH1A1IKBKBCHUKLIMK1
SCHEMBL10405198 0.71 KDM4E (0.57) KDM4EALDH1A1IKBKBCHUKLIMK1
SCHEMBL3836628 0.70 LIMK1 (0.77) KDM4EALDH1A1IKBKBCHUKLIMK1
SCHEMBL3493221 0.70 KDM4E (0.56) KDM4EALDH1A1IKBKBCHUKLIMK1
SCHEMBL15417422 0.70 KDM4E (0.56) KDM4EALDH1A1IKBKBCHUKLIMK1
SCHEMBL15931649 0.70 KDM4E (0.56) KDM4EALDH1A1IKBKBCHUKLIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213118-A1 UBIQUITIN-SPECIFIC PROTEASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOFF CHASER THERAPEUTICS, INC. (CN) 2022-07-07 US disclosed
EP-3954694-A1 UBIQUITIN-SPECIFIC PROTEASE INHIBITORS, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Chaser Therapeutics, Inc. (CN) 2022-02-16 EP disclosed
WO-2020224652-A1 UBIQUITIN-SPECIFIC PROTEASE INHIBITORS, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 北京普济远成生物科技有限公司 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213118-A1 UBIQUITIN-SPECIFIC PROTEASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOFF USP28, USP25, USP24 KDM4E 2500/4885ALDH1A1 1156/4885IKBKB 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.